Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019, with a specific reporting date of October 11, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Dividend Re-investment | Ordinary Shares (25p each) | 17.2029 | 1,213 |
Note: The total volume of 1,213 shares is the aggregate of four separate transactions executed on October 10, 2019, on the London Stock Exchange.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures for share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs via dividend re-investment on October 10, 2019.
- Confirm the transaction price of GBP 17.2029 per share aligns with the market price on the London Stock Exchange for that date.
- Identify the specific individuals involved: Ms V A Whyte (Company Secretary), Ms S Jackson (SVP, Global Communications), Mr I W Whyte (PCA), and Mrs D Connor (PCA).
- Note that this filing does not provide data on GSK's overall financial performance for the period.